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E-mail: appenzellersimone@yahoo.com (S. Appenzeller).he systemic autoinﬂammatory syndromes often present
ith recurrent fevers and high inﬂammatory markers. In
he last decades, autoinﬂammatory syndromes have been
ncreasingly recognized and the identiﬁcation of genetic
utations has helped not only the diagnosis but also to under-
tand the role of inﬂammasome and of the innate immune
ystem. Diagnosis relies on clinical suspicion followed by
enetic testing.
In this edition, the members of the Brazilian Pediatric
heumatology Committee have elaborated three publications
eviewing consensus on diagnosis and treatment of three
mportant systemic autoinﬂammatory syndromes: Famil-
al Mediterranean fever (FMF), Periodic Fever, Aphthous
tomatitis, Pharyngitis, and Adenopathy Syndrome (PFAPA)
nd cryopyrinopathies.1–3 Although extremely rare, they are
mportant to be recognized, as many  can now be completely
ontrolled by long-term drug therapies.
The consensus emphasizes the importance of clinical
uspicions in patients with recurrent or continuous signs
f systemic inﬂammation in the absence of infections and
alignancies.1–3 Duration of fever and concomitant clinical
anifestations are important features for diagnosis. Labo-
atory investigation is usually unspeciﬁc, revealing signs of
ystemic inﬂammation. Although genetic testing is costly and
ot widely available, it is often the key to establish deﬁni-
ive diagnosis in FMF  and cryopyrinopathies.2,3 However, up
o date more  than 150 mutations have been described in each
f the disease and new mutations are constantly being pub-
ished.
Treatment has shown to be effective and reduce long-term
omplications such as amyloidosis. First line treatment is
olchicine in FMF  and prednisone in PFAPA.1,3 IL1 inhibitorshave been usefully used in cryopyrinopathies, and have been
described in case series and case reports in other systemic
autoinﬂammatory diseases.1,2
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